BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 34957683)

  • 1. Mesothelioma with ALK gene mutations in two pediatric patients: Clinical course and outcome.
    Kimpo MS; Francisco KL; Chong QT; Lian DWQ; Lin NY; Mali V; Loh DL; Prabhakharan K
    Pediatr Blood Cancer; 2022 Jul; 69(7):e29544. PubMed ID: 34957683
    [No Abstract]   [Full Text] [Related]  

  • 2. Status of Anaplastic Lymphoma Kinase (ALK) in malignant mesothelioma.
    Varesano S; Leo C; Boccardo S; Salvi S; Truini M; Ferro P; Fedeli F; Canessa PA; Dessanti P; Pistillo MP; Roncella S
    Anticancer Res; 2014 May; 34(5):2589-92. PubMed ID: 24778081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anaplastic lymphoma kinase (ALK) translocation in paediatric malignant peritoneal mesothelioma: a case report of novel ALK-related tumour spectrum.
    Loharamtaweethong K; Puripat N; Aoonjai N; Sutepvarnon A; Bandidwattanawong C
    Histopathology; 2016 Mar; 68(4):603-7. PubMed ID: 26179668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anaplastic Lymphoma Kinase Gene Rearrangement in Children and Young Adults With Mesothelioma.
    Mian I; Abdullaev Z; Morrow B; Kaplan RN; Gao S; Miettinen M; Schrump DS; Zgonc V; Wei JS; Khan J; Pack S; Hassan R
    J Thorac Oncol; 2020 Mar; 15(3):457-461. PubMed ID: 31783178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ALK in Mesothelioma: To FISH or Not to FISH?
    Cornelissen R; Dubbink HJ; von der Thüsen JH
    J Thorac Oncol; 2020 Oct; 15(10):e168-e169. PubMed ID: 32981606
    [No Abstract]   [Full Text] [Related]  

  • 6. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
    Hung YP; Dong F; Watkins JC; Nardi V; Bueno R; Dal Cin P; Godleski JJ; Crum CP; Chirieac LR
    JAMA Oncol; 2018 Feb; 4(2):235-238. PubMed ID: 28910456
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NTRK and ALK rearrangements in malignant pleural mesothelioma, pulmonary neuroendocrine tumours and non-small cell lung cancer.
    Leal JL; Peters G; Szaumkessel M; Leong T; Asadi K; Rivalland G; Do H; Senko C; Mitchell PL; Quing CZ; Dobrovic A; Thapa B; John T
    Lung Cancer; 2020 Aug; 146():154-159. PubMed ID: 32540558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FISH Analysis of Crizotinib Target Genes ROS1/ALK/MET in Malignant Mesothelioma.
    Salvi S; Varesano S; Boccardo S; Ravetti JL; Canessa PA; Pistillo MP; Ferro P; Fedeli F; Roncella S
    J Thorac Oncol; 2017 Aug; 12(8):e116-e118. PubMed ID: 28748818
    [No Abstract]   [Full Text] [Related]  

  • 9. ALK rearrangement in a pure squamous cell carcinoma: the challenge of detection of ALK rearrangement.
    Kim H; Park E; Kim YJ; Chung JH
    Virchows Arch; 2013 May; 462(5):597-9. PubMed ID: 23605565
    [No Abstract]   [Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements in lung cancer with nodular ground-glass opacity.
    Ko SJ; Lee YJ; Park JS; Cho YJ; Yoon HI; Chung JH; Kim TJ; Lee KW; Kim K; Jheon S; Kim H; Lee JH; Lee CT
    BMC Cancer; 2014 May; 14():312. PubMed ID: 24885886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of anaplastic lymphoma kinase gene rearrangement in non-small-cell lung carcinomas: a comparative study between small biopsy and excision samples.
    Abe H; Kawahara A; Azuma K; Taira T; Takase Y; Fukumitsu C; Murata K; Yamaguchi T; Akiba J; Ishii H; Okamoto I; Hoshino T; Takamori S; Kage M
    J Thorac Oncol; 2015 May; 10(5):800-805. PubMed ID: 25898958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival Benefit of Pemetrexed in Lung Adenocarcinoma Patients With Anaplastic Lymphoma Kinase Gene Rearrangements.
    Park S; Park TS; Choi CM; Lee DH; Kim SW; Lee JS; Kim WS; Song JS; Lee JC
    Clin Lung Cancer; 2015 Sep; 16(5):e83-9. PubMed ID: 25682546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Acquired multiple mutations ALK I1171N, L1196M and G1202R mediate lorlatinib resistance in EML4-ALK-rearranged malignant pleural mesothelioma: a case report.
    Hu J; Zhang B; Yao F; Fu Y; Chen D; Li D; Du N; Lizaso A; Song J; Zhang L; Li X
    Ther Adv Respir Dis; 2020; 14():1753466620935770. PubMed ID: 32600123
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
    Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
    Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Large Cell Neuroendocrine Carcinoma Harboring an Anaplastic Lymphoma Kinase (ALK) Rearrangement with Response to Alectinib.
    Hayashi N; Fujita A; Saikai T; Takabatake H; Sotoshiro M; Sekine K; Kawana A
    Intern Med; 2018 Mar; 57(5):713-716. PubMed ID: 29151522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The continuum of care for ALK-positive NSCLC: from diagnosis to new treatment options - an overview.
    Solomon B; Soria JC
    Ann Oncol; 2016 Sep; 27 Suppl 3():iii1-iii3. PubMed ID: 27573751
    [No Abstract]   [Full Text] [Related]  

  • 17. Association of EGFR mutation or ALK rearrangement with expression of DNA repair and synthesis genes in never-smoker women with pulmonary adenocarcinoma.
    Ren S; Chen X; Kuang P; Zheng L; Su C; Li J; Li B; Wang Y; Liu L; Hu Q; Zhang J; Tang L; Li X; Zhou C; Schmid-Bindert G
    Cancer; 2012 Nov; 118(22):5588-94. PubMed ID: 22569898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
    Toyokawa G; Seto T
    Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of anaplastic lymphoma kinase in pediatric cancers.
    Takita J
    Cancer Sci; 2017 Oct; 108(10):1913-1920. PubMed ID: 28756644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
    Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
    BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.